Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$113.84

38.8 (51.71%)

07:44
09/21/17
09/21
07:44
09/21/17
07:44

Alnylam price target raised to $135 from $94 at Bernstein

Bernstein analyst Vincent Chen raised his price target for Alnylam to $135 from $94 after the company announced the positive readout of the patisiran trial, with compelling efficacy, signs of reversing neuropathy, and no safety signals. Combining the increase in probability of success with a market share forecast that increasingly tilts toward Alnylam, and factoring in what is likely considerable pricing power, the analyst now forecasts about $2.7B in risk-adjusted Alnylam TTR amyloidosis sales in 2030, up from $1.5B. He reiterates an Outperform rating on the shares.

ALNY Alnylam
$113.84

38.8 (51.71%)

09/20/17
JMPS
09/20/17
NO CHANGE
Target $128
JMPS
Outperform
Alnylam price target raised to $128 from $101 at JMP Securities
JMP Securities analyst Michael King, Jr. raised his price target on Alnylam to $128 from $101 after the company reported that its Apollo trial of patisiran hit its primary and all of its secondary endpoints. Not only did the trial show that patisiran can reverse disease progression, the drug's safety profile is "very encouraging," giving it the potential to be a "best-in-class treatment," said the analyst, who keeps an Outperform rating on the stock.
09/20/17
NEED
09/20/17
NO CHANGE
Target $125
NEED
Buy
Alnylam price target raised to $125 from $85 at Needham
09/21/17
LEHM
09/21/17
NO CHANGE
Target $127
LEHM
Overweight
Alnylam price target raised to $127 from $105 at Barclays
Barclays analyst Gena Wang raised her price target for Alnylam Pharmaceuticals (ALNY) to $127 citing the company's positive topline data from the Apollo Phase study in TTR amyloidosis. The analyst increased patisiran's probability of success to 95% from 85% and reiterates an Overweight rating on the shares. Wang also decreased her price target on Equal Weight-rated Ionis Pharmaceuticals (IONS) to $52 from $55 saying Alnylam's data suggest strong competition for inotersen.
09/21/17
NOMU
09/21/17
NO CHANGE
Target $56
NOMU
Reduce
Alnylam 'substantially overvalued' after yesterday's rally, says Nomura Instinet
Nomura Instinet analyst Christopher Marai tells investors to sell shares of Alnylam Pharmaceuticals following yesterday's rally. Anylam's Phase 3 Apollo trial results for patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy met all primary and secondary endpoints at 18 months, though only showed trends toward benefit at nine months, Marai writes in a research note. He believes it is too early to ascribe any valuation to the unanalyzed results of the cardiac subgroup, but notes "it appears the stock has priced them in, in the move post data." Alnylam is now "substantially overvalued," Marai says. He keeps a Reduce rating on the shares with a $56 price target. The stock closed yesterday up 52%, or $38.80, to $113.84.

TODAY'S FREE FLY STORIES

CAR

Avis Budget

$39.94

-0.08 (-0.20%)

15:34
02/21/18
02/21
15:34
02/21/18
15:34
Options
Avis Budget options imply 12.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VBTX

Veritex

$27.59

-0.48 (-1.71%)

15:33
02/21/18
02/21
15:33
02/21/18
15:33
Conference/Events
Veritex management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 24

    Sep

VBTX

Veritex

$27.59

-0.48 (-1.71%)

15:29
02/21/18
02/21
15:29
02/21/18
15:29
Conference/Events
Veritex management to meet with Stephens »

Meeting to be held in St.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 27

    Feb

  • 24

    Sep

OMER

Omeros

$11.37

0.36 (3.27%)

15:29
02/21/18
02/21
15:29
02/21/18
15:29
Periodicals
Omeros has 'plunging' Omidria sales, 'shaky' balance sheet, Feuerstein says »

Adam Feuerstein of STAT…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TI

Telecom Italia

$8.84

-0.11 (-1.23%)

15:27
02/21/18
02/21
15:27
02/21/18
15:27
Hot Stocks
Telecom Italia says not involved in any anticompetitive behavior »

Regarding today's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KS

KapStone

$34.69

0.14 (0.41%)

15:24
02/21/18
02/21
15:24
02/21/18
15:24
Conference/Events
KapStone management to meet with Stephens »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCBK

TriCo Bancshares

$37.24

-0.76 (-2.00%)

15:19
02/21/18
02/21
15:19
02/21/18
15:19
Conference/Events
TriCo Bancshares management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

AAOI

Applied Optoelectronics

$33.33

1.34 (4.19%)

15:19
02/21/18
02/21
15:19
02/21/18
15:19
Options
Applied Optoelectronics options imply 22.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 13

    Mar

  • 29

    Mar

$NSD

NASDAQ Market Internals

15:17
02/21/18
02/21
15:17
02/21/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$272.87

1.47 (0.54%)

, SPX

S&P 500

15:16
02/21/18
02/21
15:16
02/21/18
15:16
Technical Analysis
Technical Take: S&P 500 retests lows of the day »

At time of writing the…

SPY

SPDR S&P 500 ETF Trust

$272.87

1.47 (0.54%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$272.87

1.47 (0.54%)

, SPX

S&P 500

15:16
02/21/18
02/21
15:16
02/21/18
15:16
Technical Analysis
Technical Take: S&P 500 retests lows of the day »

At time of writing the…

SPY

SPDR S&P 500 ETF Trust

$272.87

1.47 (0.54%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
02/21/18
02/21
15:16
02/21/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABG

Asbury Automotive

$68.25

0.3 (0.44%)

15:15
02/21/18
02/21
15:15
02/21/18
15:15
Conference/Events
Asbury Automotive management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:15
02/21/18
02/21
15:15
02/21/18
15:15
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

WFC

Wells Fargo

$60.35

0.4 (0.67%)

15:10
02/21/18
02/21
15:10
02/21/18
15:10
Options
Notable call write in Wells Fargo »

Notable call write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 06

    Mar

  • 07

    Mar

  • 15

    Mar

  • 30

    May

AZN

AstraZeneca

$34.09

0.45 (1.34%)

15:08
02/21/18
02/21
15:08
02/21/18
15:08
Hot Stocks
AstraZeneca announces renewed recommendation, availability of FLUMIST vaccine »

AstraZeneca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 23

    Apr

P

Pandora

$4.96

-0.375 (-7.04%)

15:04
02/21/18
02/21
15:04
02/21/18
15:04
Options
Pandora options imply 26.6% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Feb

  • 26

    Feb

  • 05

    Mar

BA

Boeing

$358.70

5.35 (1.51%)

, EADSY

Airbus

$29.67

0.08 (0.27%)

15:03
02/21/18
02/21
15:03
02/21/18
15:03
Periodicals
Boeing displaces Airbus at Hawaiian, Leeham News and Comment says »

Boeing (BA) has displaced…

BA

Boeing

$358.70

5.35 (1.51%)

EADSY

Airbus

$29.67

0.08 (0.27%)

HA

Hawaiian Holdings

$37.35

-1.3 (-3.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 30

    May

NFLX

Netflix

$278.55

0.03 (0.01%)

15:03
02/21/18
02/21
15:03
02/21/18
15:03
Periodicals
Netflix and indie film makers Duplass Brothers in deal, Variety reports »

Variety reported earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

  • 20

    Mar

MBT

Mobile TeleSystems

$12.66

0.49 (4.03%)

15:00
02/21/18
02/21
15:00
02/21/18
15:00
Options
Call buyers in Mobile TeleSystems as shares reach 52-week highs »

Call buyers in Mobile…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPZ

Domino's Pizza

$223.26

1.77 (0.80%)

, QSR

Restaurant Brands

$59.54

0.31 (0.52%)

14:50
02/21/18
02/21
14:50
02/21/18
14:50
Periodicals
Restaurant Brands deal for Domino's 'likely,' 680 NEWS Toronto reporter says »

Richard Southern of 680…

DPZ

Domino's Pizza

$223.26

1.77 (0.80%)

QSR

Restaurant Brands

$59.54

0.31 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 07

    Mar

  • 30

    May

ROKU

Roku

$51.18

3.05 (6.34%)

14:49
02/21/18
02/21
14:49
02/21/18
14:49
Options
Roku Inc (Class A Stock) options imply 26.4% move in share price post-earnings, below median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

  • 21

    Mar

CGG

CGG SA

$3.97

-0.24 (-5.70%)

14:45
02/21/18
02/21
14:45
02/21/18
14:45
Hot Stocks
Breaking Hot Stocks news story on CGG SA 

CGG SA trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$117.30

2.59 (2.26%)

14:45
02/21/18
02/21
14:45
02/21/18
14:45
Recommendations
JPMorgan analyst commentary  »

JPMorgan price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 25

    Feb

  • 27

    Feb

  • 07

    Mar

  • 13

    Mar

  • 13

    Apr

  • 30

    May

  • 14

    Jul

  • 12

    Oct

NGVT

Ingevity

$77.41

5.14 (7.11%)

14:42
02/21/18
02/21
14:42
02/21/18
14:42
Hot Stocks
Ingevity sees $1.5B in revenue, adjusted EBITDA $500M in 2022 »

Comments are from the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.